Nephrologists have developed CRRT protocols to provide renal replacement therapy in the ICU in order to minimize metabolic and electrolyte disturbances in patients with acute renal failure.

The choice of hemofiltration solutions for these protocols must meet the needs of each patient, the ICU and the pharmacy. As CRRT protocols evolve to higher volume per hour of therapy, the composition of solutions becomes more important. Normocarb HF does not contain lactate or dextrose, ingredients that can confuse the clinical picture and potentially lead to dangerous and unnecessary investigations. Normocarb HF is protocol-neutral, allowing you to integrate this safe and effective solution into your own preferred CRRT protocol. No other infusate for CRRT has the volume of clinical research to support its integration into your CRRT protocols, particularly in maintenance patients.

Normocarb HF is the only product that provides a maintenance level of bicarb that works well with citrate protocols.

Quote

"My primary concern is patient care, and that means having the right solution at the right time for my patients. The absence of unnecessary and potentially dangerous components makes Normocarb HF my preferred choice of solution. The needs of any single patient change from therapy initiation to the maintenance phase, and having a solution that can be used throughout the treatment cycle makes everyone's job easier. I know I can trust a solution that has been extensively reviewed and presented in peer-reviewed journals to provide the kind of complete electrolyte control my patients require."

FLEXIBLE • SAFE • PROTOCOL NEUTRAL

Normocarb HF is a pharmaceutical-grade,
clinically-tested, FDA approved, protocol-neutral
hemofiltration solution for CRRT.

Normocarb HF

Sign-up for eNews

Nephrologists have developed CRRT protocols to provide renal replacement therapy in the ICU in order to minimize metabolic and electrolyte disturbances in patients with acute renal failure.

Quote

FLEXIBLE • SAFE • PROTOCOL NEUTRAL

Normocarb HF is a pharmaceutical-grade, clinically-tested, FDA approved, protocol-neutral hemofiltration solution for CRRT.

Normocarb HF

Sign-up for eNews

Nephrologists have developed CRRT protocols to provide renal replacement therapy in the ICU in order to minimize metabolic and electrolyte disturbances in patients with acute renal failure.

Quote

Normocarb HF is a pharmaceutical-grade,
clinically-tested, FDA approved, protocol-neutral
hemofiltration solution for CRRT.